CA2993272C - Nouveaux anticorps anti-pd-l1 - Google Patents

Nouveaux anticorps anti-pd-l1

Info

Publication number
CA2993272C
CA2993272C CA2993272A CA2993272A CA2993272C CA 2993272 C CA2993272 C CA 2993272C CA 2993272 A CA2993272 A CA 2993272A CA 2993272 A CA2993272 A CA 2993272A CA 2993272 C CA2993272 C CA 2993272C
Authority
CA
Canada
Prior art keywords
antibody
antigen
seq
cancer
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2993272A
Other languages
English (en)
Other versions
CA2993272A1 (fr
Inventor
Yong Zheng
Jing Li
Zhisheng Chen
Original Assignee
Wuxi Biologics Shanghai Co Ltd
Wuxi Biologics Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2015/086216 external-priority patent/WO2017020291A1/fr
Application filed by Wuxi Biologics Shanghai Co Ltd, Wuxi Biologics Ireland Ltd filed Critical Wuxi Biologics Shanghai Co Ltd
Publication of CA2993272A1 publication Critical patent/CA2993272A1/fr
Application granted granted Critical
Publication of CA2993272C publication Critical patent/CA2993272C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne des anticorps monoclonaux contre la protéine PD-L1 (programmed cell death 1 ligand), qui peuvent bloquer la liaison de PD-L1 à PD-1, et par conséquent bloquer la fonction inhibitrice de PD-L1 sur les lymphocytes T exprimant PD-1. Les anticorps de l'invention fournissent des agents très puissants pour le traitement de multiples cancers par modulation de la fonction immunitaire humaine.
CA2993272A 2015-08-06 2016-08-05 Nouveaux anticorps anti-pd-l1 Active CA2993272C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2015/086216 2015-08-06
PCT/CN2015/086216 WO2017020291A1 (fr) 2015-08-06 2015-08-06 Nouveaux anticorps anti-pd-l1
PCT/CN2016/093560 WO2017020858A1 (fr) 2015-08-06 2016-08-05 Nouveaux anticorps anti-pd-l1

Publications (2)

Publication Number Publication Date
CA2993272A1 CA2993272A1 (fr) 2017-02-09
CA2993272C true CA2993272C (fr) 2026-03-31

Family

ID=

Similar Documents

Publication Publication Date Title
US12180282B2 (en) Anti-PD-L1 antibodies
US20230348602A1 (en) Novel anti-pd-1 antibodies
US10696745B2 (en) Anti-PD-L1 antibodies
CN106432501B (zh) 新型抗pd-l1抗体
CN106432494B9 (zh) 新型抗-pd-1抗体
TWI723220B (zh) 一種新的pd-1單株抗體
HK40118198A (en) Novel anti-pd-1 antibodies
HK1257164B (en) Novel anti-pd-l1 antibodies
BR112018002824B1 (pt) Anticorpo isolado ou um fragmento de ligação, kit, usos do anticorpo e composição farmacêutica
HK1232555B (en) Novel anti-pd-l1 antibodies
HK1232555A1 (en) Novel anti-pd-l1 antibodies